Interleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission (Q24202630)

2

0 references

Zu-Yao Yang

3

0 references

Qian-Ling YE

4

0 references

Xin-Yin Wu

5

0 references

Xue-Feng Hu

6

0 references

Zhi-Min Zhai

7

0 references

Jin Ling Tang

Cochrane Database of Systematic Reviews

8

0 references

publication date

12 December 2012

0 references

published in

0 references

cites work

Age and acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248

Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248

Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248

Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248

Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248

Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248

Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248

Defective T-helper cell function after T-cell-depleting therapy affecting naive and memory populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248

Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248

Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248

21 January 2018

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248

A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248

Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248

Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248

Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248

Practical methods for incorporating summary time-to-event data into meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248

Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248

Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248

10.1002/14651858.CD010248

21 January 2018

Identifiers

DOI

0 references

Fatcat ID

release_2xb34vy2ofa6be7akqlnjiepoy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2xb34vy2ofa6be7akqlnjiepoy